Fingolimod in Endovascular Treatment of Ischemic Stroke

  • End date
    Dec 30, 2021
  • participants needed
  • sponsor
    Ning Wang, MD., PhD.
Updated on 26 January 2021


Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This study aim to determine whether fingolimod enhance the action of endovascular treatment for acute ischemic stroke

Condition Stroke Inflammation
Treatment Fingolimod
Clinical Study IdentifierNCT04629872
SponsorNing Wang, MD., PhD.
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 80 yrs?
Gender: Male or Female
Do you have any of these conditions: Do you have Stroke Inflammation??
Patients presenting with anterior circulation acute ischaemic stroke who are eligible for mechanical thrombectomy commenced within 6-24 hours of stroke onset
Patient, family member or legally responsible person depending on local ethics requirements has given informed consent
Patient's age is 18-80 years
Arterial occlusion on internal carotid artery proximal or middle cerebral artery
Imaging inclusion criteria: infarct core volume between 15-70 mL

Exclusion Criteria

Pre-existing neurologic disability (a score greater than 2 on the mRS)
Swallowing difficulties that would prevent administration of oral fingolimod
Patients with any history of bradyarrhythmia, atrioventricular block or current use of beta-blockers or verapamil
Patients with serious acute or chronic infection, or hepatic injury
Concomitant use of antineoplastic, immunosuppressive or immune modulating therapies
Macular edema
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note